Screener
CorMedix CRMD R&D capitalization
R&D capitalization at other companies
Other financials
Where this comes from
Reported directly by CorMedix in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts.
The source filing: CorMedix’s 10-K, filed March 5, 2026.
- Filed
- Mar 5, 2026, 8:32 AM EST
- Fiscal year
- FY2025
- Accession
- 0001213900-26-023889
| Line item | December 31, 2025 | December 31, 2024 |
|---|---|---|
| Total gross deferred tax assets | 181,093 | 69,168 |
| Less valuation allowance | (113,330) | (69,168) |
| Total Deferred tax assets net of valuation allowance | $67,763 | - |
| Deferred tax liabilities | ||
| In Process R&D | (36,281) | - |
| Intangible asset | (15,206) | - |
| Total gross deferred tax liabilities | (51,487) | - |
| Net deferred tax assets | 16,276 | - |
Item 16. Form 10-K Summary
FAQ
- What is CorMedix's r&d capitalization?
- CorMedix (CRMD) reported r&d capitalization of $36.28M in Q4 2025.
- What does r&d capitalization mean?
- This represents the portion of research and development expenditures that have been capitalized as assets on the balance sheet rather than expensed immediately. It reflects the company's accounting treatment of long-term development costs that are expected to provide future economic benefits. Tracking this helps investors understand the company's investment in its pipeline and the potential for future amortization charges.
Ask your AI about CorMedix's r&d capitalization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude